)
Contineum Therapeutics (CTNM) investor relations material
Contineum Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
PIPE-791 is the lead wholly owned candidate; PROPEL-IPF patient dosing began in Q1 2026, with trial completion targeted for June 2028.
J&J’s Phase 2 MOONLIGHT-1 trial of PIPE-307 in major depressive disorder missed its primary endpoint; it was well tolerated, and J&J is reviewing exploratory data before deciding next steps.
Cash, cash equivalents and marketable securities totaled $244.5 million at September 30, 2026; management projects funding for planned operations through mid-2029.
Financial highlights
Q3 2026 operating expenses were $21.0 million versus $14.9 million YoY; net loss was $18.7 million versus $12.8 million.
Q3 R&D expense was $16.0 million, up 45% YoY, primarily from PIPE-791 development and employee-related costs; G&A was $5.0 million, up 26%, mainly from stock compensation and employee costs.
9M 2026 operating expenses were $55.3 million versus $50.9 million; net loss was $48.3 million versus $44.8 million.
9M R&D expense was $40.3 million versus $38.8 million; G&A was $15.0 million versus $12.2 million, with higher stock compensation and personnel costs contributing to the increase.
No revenue was recognized in Q3 or 9M 2026; interest income was $2.4 million for Q3 and $7.2 million for 9M.
Outlook and guidance
Management expects available cash resources to fund planned operations through mid-2029, one year beyond the estimated completion of the IPF trial.
PROPEL-IPF evaluates once-daily oral PIPE-791 over 26 weeks in approximately 324 IPF patients; completion remains targeted for June 2028.
Operating expenses, particularly R&D, are expected to increase substantially as clinical development, pipeline work, headcount and public-company activities continue.
Future funding may come from equity, debt or commercial arrangements; financing may be unavailable or require dilution or concessions on program rights.
- PIPE-791 pairs an active Phase 2 IPF program with early chronic-pain signals.CTNM
Corporate presentation - PIPE-791 advances in IPF with strong differentiation, robust funding, and strategic focus on PROPEL-IPF.CTNM
Morgan Stanley 24th Annual Global Healthcare Conference - Net loss narrowed, global trials advanced, and $236.6M cash runway extends through mid-2029.CTNM
Q2 2026 - Multiple clinical milestones expected in the next 12 months for neuroscience and immunology programs.CTNM
Cantor Global Healthcare Conference 2025 - Multiple Phase II trials and strong funding position drive momentum in neuroscience and immunology.CTNM
7th Annual Evercore ISI HealthCONx Healthcare Conference - Multiple clinical milestones ahead for neuroscience and immunology assets, with strong funding.CTNM
Baird Global Healthcare Conference 2025 - PIPE-791 advances in IPF with strong differentiation, robust pipeline, and solid financial runway.CTNM
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - PIPE-791 shows strong safety, efficacy signals, and differentiation in IPF and pain studies.CTNM
RBC Capital Markets Global Healthcare Conference 2026 - PIPE-791 and PIPE-307 advance in IPF, pain, and MDD, with strong financial backing and J&J partnership.CTNM
Corporate presentation
Next Contineum Therapeutics earnings date
Next Contineum Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)